LOXO-305 Comes Out Swinging In Battle Of BTK Inhibitors
Lilly's Loxo Presents Positive Phase I/II Data In MCL At ASH
Executive Summary
Pathway open for drug as post-covalent BTK option as Loxo gears up for "risky" Phase III head-to-head study in Q1 2021.
You may also be interested in...
Lilly’s 2021 Double-Digit Growth Comes From COVID-19 Drugs, New Products
Most of Lilly’s 2021 gains will come from its newer products, but sales of COVID-19 treatments added $500m to the company’s 2020 revenue guidance and may total $1bn-$2bn next year.
Lilly’s Multi-Tumor Treatment Retsevmo Closer To EU Approval
Approved in the US in May, the drug is the latest targeted therapy to emerge from Lilly’s oncology division Loxo.
Gilead/Kite Gain Second CAR-T Approval With Tecartus, Price On Par With Their First
As the first company with two approved chimeric antigen receptor T-cell therapies, Gilead’s Kite subsidiary has set a precedent by keeping the pricing the same as its first approved CAR-T, Yescarta.